Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Aug 31;13(8):2082-2086.
doi: 10.21037/tlcr-24-144. Epub 2024 Jul 26.

REGN5093-M114: can an antibody-drug conjugate overcome the challenge of resistance to epidermal growth factor receptor and mesenchymal epithelial transition tyrosine kinase inhibitors in non-small cell lung cancer?

Julie Dardare  1 , Andréa Witz  1   2 , Alexandre Harlé  1   2
Affiliations
Editorial

REGN5093-M114: can an antibody-drug conjugate overcome the challenge of resistance to epidermal growth factor receptor and mesenchymal epithelial transition tyrosine kinase inhibitors in non-small cell lung cancer?

Julie Dardare et al. Transl Lung Cancer Res. .
No abstract available

Keywords: Epidermal growth factor receptor (EGFR); REGN5093-M114; mesenchymal epithelial transition (MET); non-small cell lung cancer (NSCLC); resistance.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tlcr.amegroups.com/article/view/10.21037/tlcr-24-144/coif). A.H. received consulting fees from Amgen and Janssen; received payment for lectures from Amgen, AstraZeneca, Janssen and Pierre Fabre; and received support for attending meetings from AstraZeneca. The other authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Potential targets for REGN5093-M114 in the management of patients with NSCLC. REGN5093-M114 is an ADC that targets two distinct epitopes of MET factor. It is conjugated with a novel maytansine derivative (M24) using the M114 protease-cleavable linker, with an average drug: antibody ratio of approximately 3.2. The administration of EGFR-TKI with or without MET TKI combination can lead to several resistance mechanisms. REGN5093-M114 may be effective against the listed alterations and counter resistance to EGFR and MET TKI. NSCLC, non-small cell lung cancer; MET, mesenchymal epithelial transition; MFI, mean fluorescence intensity; CNV, copy number variation; EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor; ADC, antibody-drug conjugate.
See this image and copyright information in PMC

Comment on

References

    1. Oh SY, Lee YW, Lee EJ, et al. Preclinical Study of a Biparatopic METxMET Antibody-Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC. Clin Cancer Res 2023;29:221-32. 10.1158/1078-0432.CCR-22-2180 - DOI - PubMed
    1. Wu YL, Cheng Y, Zhou X, et al. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. Lancet Oncol 2017;18:1454-66. 10.1016/S1470-2045(17)30608-3 - DOI - PubMed
    1. Park K, Tan EH, O'Byrne K, et al. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncol 2016;17:577-89. 10.1016/S1470-2045(16)30033-X - DOI - PubMed
    1. Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature 2018;553:446-54. 10.1038/nature25183 - DOI - PubMed
    1. Recondo G, Che J, Jänne PA, et al. Targeting MET Dysregulation in Cancer. Cancer Discov 2020;10:922-34. 10.1158/2159-8290.CD-19-1446 - DOI - PMC - PubMed

LinkOut - more resources